fashion -WSS

fashion

author：focus 2025-09-30 12:10:42 - browse：9122

Drugmakers already bet big on mRNA for cancer. Now President Biden is going in, too? Anna Moneymaker/Getty Images

WASHINGTON — President Biden’s fledgling health agency, designed to accelerate under-funded research, just set its sights on one of the hottest areas of medicine — and one where the drug industry has a multibillion-dollar head start.

The White House announced Wednesday that the Advanced Research Projects Agency for Health would bankroll a $24 million project by Emory University to build messenger RNA platforms to target “cancer and other diseases,” investing in the technology behind the U.S.’s most commonly used vaccines for Covid-19.

The administration touted the news of CUREIT as the latest in Biden’s longtime mission to rein in cancer deaths, the Cancer Moonshot. But by using mRNA to treat cancer, ARPA-H is wading into a field that has advanced in fits and starts — and whose industry leaders have already spent multiples of the program’s entire budget into their own research. Moderna and BioNTech, massively profitable companies that have sold more than $80 billion worth of Covid-19 vaccines combined, have singled out oncology as the next big application for mRNA and invested accordingly.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Cord blood banking comes at a high cost to babies

entertainment

WSS

Liquid biopsy for lung cancer is launched by Delfi

Physician executives need more than on

The Pandemic Treaty must support building strong health systems

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Innovation in antibiotics is ailing. 'Brain drain' may kill it

The Pandemic Treaty must support building strong health systems

Wikipedia

fashion

hotspot

Walensky prepares to leave CDC — and Congress — behind

Why Charlie Gard's case is so disturbing to Americans

Medical leaders decry Supreme Court decision on affirmative action

FDA's Pazdur wants cancer trials to range beyond China alone

Jerome Adams on the need for new antivirals for Covid

Bristol 'take

Medicare details structure of new drug price negotiation program

What to expect at HLTH 2023, the health care industry conference

The high cost of giving birth even with insurance

At ASCO, AstraZeneca reports strong data for breast cancer drug

entertainment

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

See how much Covid

ASCO: AstraZeneca says CAR

What to expect at HLTH 2023, the health care industry conference

3 questions for the future of Biden's cancer moonshot

Was Amgen transparent enough on FDA's concern on cancer drug?

hotspot

entertainment

focus

focus